(missing name)

I am a molecular biologist with 10 years experience in cancer research and a focus on breast and colon tumour suppressor genes, including BRCA1/2, MSH2/RAD51 and MCC. My career aim is to understand how mutations in key genes lead to cancer and how deregulated signalling pathways in tumours can be ex

Biography

I am a molecular biologist with 10 years experience in cancer research and a focus on breast and colon tumour suppressor genes, including BRCA1/2, MSH2/RAD51 and MCC. My career aim is to understand how mutations in key genes lead to cancer and how deregulated signalling pathways in tumours can be exploited to improve treatment strategies. My work in this field has been rewarded with high impact publications in high-ranking journals such as Nature, Molecular Cell Research and Human Molecular Genetics.

I am now running my own research group looking at new “actionable” cancer molecular targets by integrating data from large scale siRNA screens and the largest resource of publicly available tumor genomic data (TCGA), with a special focus on the Wnt/beta-catenin signalling pathway. Thanks to a highly driven team and a growing collaborative network I have identified new putative oncogenes, which I predict could lead to my most significant findings to date in regard to improving cancer therapy management.

I am a molecular biologist with 10 years experience in cancer research and a focus on breast and colon tumour suppressor genes, including BRCA1/2, MSH2/RAD51 and MCC. My career aim is to understand how mutations in key genes lead to cancer and how deregulated signalling pathways in tumours can be exploited to improve treatment strategies. My work in this field has been rewarded with high impact publications in high-ranking journals such as Nature, Molecular Cell Research and Human Molecular Genetics.

I am now running my own research group looking at new “actionable” cancer molecular targets by integrating data from large scale siRNA screens and the largest resource of publicly available tumor genomic data (TCGA), with a special focus on the Wnt/beta-catenin signalling pathway. Thanks to a highly driven team and a growing collaborative network I have identified new putative oncogenes, which I predict could lead to my most significant findings to date in regard to improving cancer therapy management.

Awards and Honours

2013-2014 - Project Grant CIA - Co-funded Cure cancer / Cancer Australia. Priority-driven Young Investigator Project Grant Applications
2012-2014 - Project Grant CIB - NHMRC – National Health Medical Research
2010-2012 - Project Grant CIA - Cancer Council NSW
Establishment Grant CIA - Clive and Vera Ramaciotti Foundation

Education

2007 - PhD, King’s College London - UK
2001 - DESS IAB:“Diplome d’Etude Superieur Specialise” in Bioinfomormatics, University Jussieux-Versailles - France
2000 - “Maitrise” equivalent Master in Molecular Biology, University of Montreal - Canada
1999 - “Deug” equivalent Degree in Cellular Biology, University Joseph Fourier - France

Selected Publications

Mladenova D, Pangon L, Currey N, Ng I, Musgrove EA, Grey ST, Kohonen-Corish MR. Sulindac activates N  F-kappaB signaling in colon cancer cells. Cell Commun Signal. 201; 11(1):73.

Macia L, Yulyaningsih E, Pangon L, Nguyen AD, Lin S, Shi YC, Zhang L, Bijker M, Grey S, Mackay F, Herzog H, Sainsbury A.Neuropeptide Y1 receptor in immune cells regulates inflammation and insulin resistance associated with diet-induced obesity.Diabetes. 2012; 61(12):3228-38.

Poursoltan P, Currey N, Pangon L, van Kralingen C, Selinger CI, Mahar A, Cooper WA, Kennedy CW, McCaughan BC, Trent R, Kohonen-Corish MR. Loss of heterozygosity of the Mutated in Colorectal Cancer gene is not associated with promoter methylation in non-small cell lung cancer. Lung Cancer. 2012; 77(2):272-6.

Pangon L, Van Kralingen C, Abas M, Daly RJ, Musgrove EA, Kohonen-Corish MR. The PDZ-binding motif of MCC is phosphorylated at position -1 and controls lamellipodia formation in colon epithelial cells. Biochim Biophys Acta. MCB 2012; 1823(6):1058-67.

Sigglekow ND, Pangon L, Brummer T, Molloy M, Hawkins NJ, Ward RL, Musgrove EA, Kohonen-Corish MR. Mutated in colorectal cancer protein modulates the NFκB pathway. Anticancer Res. 2012; 32(1):73-9.

Pangon L, Sigglekow ND, Larance M, Al-Sohaily S, Mladenova DN, Selinger CI, Musgrove EA, Kohonen-Corish MR. The "Mutated in Colorectal Cancer" Protein Is a Novel Target of the UV-Induced DNA Damage Checkpoint. Genes Cancer. 2010; 1(9):917-26.

Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011; 6(7):1179-89.

Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T, Ng T, Solomon E. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature. 2009; 462(7275):886-90

Barwell J, Pangon L, Georgiou A, Docherty Z, Kesterton I, Ball J, Camplejohn R, Berg J, Aviv A, Gardner J, Kato BS, Carter N, Paximadas D, Spector TD, Hodgson S. Is telomere length in peripheral blood lymphocytes correlated with cancer susceptibility or radiosensitivity? Br J Cancer. 2007;  97(12): 1696-700.

Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris JR, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeles R, Hodgson SV. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. 2007; 121(7):1631-6.

Pangon L*, Barwell J*, Hodgson S, Georgiou A, Kesterton I, Slade T, Taylor M, Payne SJ, Brinkman H, Smythe J, Sebire NJ, Solomon E, Docherty Z, Camplejohn R, Homfray T, Morris JR. Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics. J Med Genet. 2007; 44(8):516-20.

Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, Ball J, Barwell J, Gilchrist R, Pangon L, Berg J, Hodgson S.Is chromosome radiosensitivity and apoptotic response to irradiation correlated with cancer susceptibility? Int J Radiat Biol. 2007; 83(1):1-12

Pangon L*, Morris JR*, Boutell C, Katagiri T, Keep N, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006;  15(4): 599-606.